We learn of several reasons why cell line derived standards have a distinct advantage on other source materials when it comes to NGS oncology assays.
Learn how reference standards play a key role in increasing and confirming the accuracy of diagnostic testing, thus bringing us closer to precision medicine and targeted therapy.
Liquid biopsy is fast becoming a realistic clinical diagnostic tool, capable of profiling the molecular makeup of a tumor that aids in choosing the right drug and in monitoring treatment response. Studies for its use in early cancer detection are already underway with promising results.
Acute Myeloid Leukaemia (AML) is a group of blood cancer malignancies that originate from the uncontrolled proliferation of blast cells in the bone marrow and circulating blood1. AML is a relatively rare disorder - representing less than 1% of total cancer cases.
See from a real example how Horizon's reference standards can be used to validate a new NGS assay technology.
Top ten recommendations to validate your NGS assay.
Liquid biopsies are becoming increasingly popular in cancer research. We take a look at their potential impact in the clinic and how current technologies can help us keep pushing the boundaries of precision medicine.
Next-generation sequencing (NGS), has become a universal tool in diverse industries; most recently moving into the clinic for patient diagnosis. However, if labs wish to analyze patient-derived materials they must first face a hurdles labs to optimize and validate their workflow including determining the exact test limitations.
The high-throughput and increasingly affordable nature of next-generation sequencing (NGS) has led to its expanded use in routine clinical procedures. The relative simplicity of targeted enrichment cancer panels (available from a number of commercial providers) allows routine laboratories to simultaneously analyze the coding (exonic) regions of multiple cancer-related key genes. Combine this with the statistic diagnostic testing now influencing over 70 percent of all health care decisions1, the setting up or transitioning to NGS-based oncology panels for labs has never been more important.